Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
New cleanroom facility allows production of one million doses per year Ramping up for clinical development in osteoarthritis in 2026 Supports launch of Synoglide™ in veterinary markets worldwide Liege, Belgium – 9 January 2026 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology treatments for degenerative joint disease, will officially launch production of its first microparticle hydrogel after a ceremonial opening of its cleanroom manufacturing facility on 9 January 2026. After an investment worth multiple millions of euros, the state-of-the art facility enables annual production of a million prefilled syringes per year. The production will amongst others supply partner American Regent with Synoglide™, a novel treatment for osteoarthritis in the equine market, which has been launched recently in the US, for commercialization in veterinary markets worldwide. “We are honored that Minister Jeholet will be with us as we celebrate this moment,
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerBusiness Wire
- Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern EuropeBusiness Wire
- DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer [Yahoo! Finance]Yahoo! Finance